Stock in focus: Bayer celebrates stock exchange mathematics that shareholders should know
After a costly poison pill acquired a good decade ago, there is a lot of good news from the life science group. But it's still a long way to old record highs.
Düsseldorf: Bayer's stock is poised to be a major winner in 2026, with the potential for over 100% growth over the past year. The company's share price has nearly tripled since early 2025 and is currently near its all-time high. Despite this, Bayer remains far from its peak, which was reached in April 2015 when investors paid up to 145.80 Euros per share.
That was when the life-science company was Germany's most valuable concern. The acquisition of Monsanto, an American seed and pesticide producer, for 63 billion dollars in 2018 was intended to create a global giant but instead led to a toxic situation. The company's stock plummeted almost 87% to 18.85 Euros in the following decade, primarily due to widespread lawsuits over Monsanto's herbicide glyphosate in the United States.
While the stock has since recovered more than 200%, it still falls short of the previous peak by nearly 160%.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
